Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population.
Authors
- Chi‐Ho Lee (ORCID: https://orcid.org/0000-0002-7569-409X)
- Rex Wan‐Hin Hui (ORCID: https://orcid.org/0000-0001-7447-7539)
- Wai K. Leung (ORCID: https://orcid.org/0000-0002-5993-1059)
- Chi‐Leung Chiang (ORCID: https://orcid.org/0000-0002-9836-6478)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Ka Shing Cheung (ORCID: https://orcid.org/0000-0002-4838-378X)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Xianhua Mao (ORCID: https://orcid.org/0000-0003-4050-4759)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
- Jing‐Tong Tan
- Ho‐Ming Cheng
Institutions
- Chinese University of Hong Kong (HK)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1111/apt.18254
- Citations
- 8
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- Alexion Pharmaceuticals
- Merck KGaA
- Arrowhead Pharmaceuticals
- Sysmex Corporation